Abcellera Biologics Inc
$ 4.15
2.47%
24 Apr - close price
- Market Cap 1,261,148,000 USD
- Current Price $ 4.15
- High / Low $ 4.29 / 3.97
- Stock P/E N/A
- Book Value 3.22
- EPS -0.49
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.14 %
- 52 Week High 6.51
- 52 Week Low 1.94
About
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$9.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-06 | 2025-08-07 | 2025-05-05 | 2025-02-18 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.03 | -0.19 | -0.12 | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 | -0.17 | -0.1 | -0.11 | -0.14 |
| Estimated EPS | -0.144 | -0.14 | -0.14 | -0.17 | -0.1471 | -0.15 | -0.14 | -0.17 | -0.13 | -0.13 | -0.13 | -0.14 |
| Surprise | 0.114 | -0.05 | 0.02 | 0.02 | 0.0271 | -0.02 | 0.01 | 0.03 | -0.04 | 0.03 | 0.02 | 0 |
| Surprise Percentage | 79.1667% | -35.7143% | 14.2857% | 11.7647% | 18.4228% | -13.3333% | 7.1429% | 17.6471% | -30.7692% | 23.0769% | 15.3846% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABCL
2026-04-25 04:09:24
Leerink Partners has downgraded AbCellera Biologics (ABCL). The downgrade reflects a revised outlook on the company's financial prospects or operational performance, as analyzed by the investment firm.
2026-04-24 16:11:00
AbCellera Biologics (ABCL) is gaining attention ahead of its interim Phase 1 data update for ABCL635, a menopause therapy candidate, on May 11. Despite recent stock gains, the company remains unprofitable and its current P/S ratio is significantly higher than industry averages, raising questions about whether its valuation accurately reflects future growth potential. Simply Wall St's fair value assessment suggests ABCL is 58.5% undervalued at $9.83, but rapid changes could occur if ABCL635 data disappoints or high R&D spending continues.
2026-04-24 12:39:39
AbCellera Biologics is transitioning from a partnership-driven drug discovery model to developing its own internal clinical pipeline, leveraging its end-to-end capabilities and substantial liquidity. The company's lead candidate, ABCL635, an anti-NK3R antibody for menopausal hot flashes, is expected to release Phase II data in Q3, with management projecting a significant U.S. addressable market. AbCellera plans to use the Phase II results to inform future registrational trials and potential expansion into related indications.
2026-04-24 12:39:15
AbCellera Biologics is shifting its strategy from a partnership-driven drug discovery model to developing its own internal clinical pipeline, supported by $700 million in liquidity and new end-to-end capabilities including an in-house GMP manufacturing facility. The company's lead candidate, ABCL635, an anti-NK3R antibody for menopausal hot flashes, is expected to have Phase II data released in Q3 2026, targeting an estimated $6 billion U.S. market. AbCellera plans to aggressively advance ABCL635 into a registrational trial by 2027 if Phase II results are positive, while also pursuing other programs in autoimmunity and oncology.
2026-04-23 15:09:53
BMO Capital has reiterated its Buy rating on AbCellera Biologics (ABCL.US) and maintained its target price of $7. This indicates a continued positive outlook from the firm regarding the company's stock performance.
2026-04-22 23:09:23
JonesTrading has reiterated its Buy rating for AbCellera Biologics (ABCL.US), maintaining a target price of $11. This indicates continued confidence in the company's stock performance and future prospects from the brokerage firm.
